Safia Barber
University of Manchester · 6 works · 1,023 citations · h-index 4
Top works
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)
- Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply
- Randomised Phase III Controlled Trial of FOLFOX as Second-line Chemotherapy for Advanced Biliary Tract Cancer
- FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer